SPRB vs. IPA, VIRX, FBIO, DARE, ACXP, BCTX, CASI, MRKR, THTX, and APLM
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), Fortress Biotech (FBIO), Daré Bioscience (DARE), Acurx Pharmaceuticals (ACXP), BriaCell Therapeutics (BCTX), CASI Pharmaceuticals (CASI), Marker Therapeutics (MRKR), Theratechnologies (THTX), and Apollomics (APLM). These companies are all part of the "pharmaceutical preparations" industry.
Spruce Biosciences (NASDAQ:SPRB) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
Spruce Biosciences presently has a consensus price target of $5.67, suggesting a potential upside of 636.03%. ImmunoPrecise Antibodies has a consensus price target of $7.00, suggesting a potential upside of 530.63%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than ImmunoPrecise Antibodies.
Spruce Biosciences received 31 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 63.33% of users gave Spruce Biosciences an outperform vote.
91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ImmunoPrecise Antibodies has a net margin of -60.23% compared to Spruce Biosciences' net margin of -461.67%. ImmunoPrecise Antibodies' return on equity of -26.54% beat Spruce Biosciences' return on equity.
Spruce Biosciences has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
In the previous week, Spruce Biosciences had 15 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 17 mentions for Spruce Biosciences and 2 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 1.43 beat Spruce Biosciences' score of 0.27 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the news media.
ImmunoPrecise Antibodies has higher revenue and earnings than Spruce Biosciences. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
ImmunoPrecise Antibodies beats Spruce Biosciences on 9 of the 17 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
